A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.
Stacey SN., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., Gudbjartsson DF., Magnusson OT., Gudjonsson SA., Sigurgeirsson B., Thorisdottir K., Ragnarsson R., Benediktsdottir KR., Nexø BA., Tjønneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., García-Prats MD., Sanambrosio E., Panadero A., De Juan A., Garcia A., Rivera F., Planelles D., Soriano V., Requena C., Aben KK., van Rossum MM., Cremers RGHM., van Oort IM., van Spronsen D-J., Schalken JA., Peters WHM., Helfand BT., Donovan JL., Hamdy FC., Badescu D., Codreanu O., Jinga M., Csiki IE., Constantinescu V., Badea P., Mates IN., Dinu DE., Constantin A., Mates D., Kristjansdottir S., Agnarsson BA., Jonsson E., Barkardottir RB., Einarsson GV., Sigurdsson F., Moller PH., Stefansson T., Valdimarsson T., Johannsson OT., Sigurdsson H., Jonsson T., Jonasson JG., Tryggvadottir L., Rice T., Hansen HM., Xiao Y., Lachance DH., O Neill BP., Kosel ML., Decker PA., Thorleifsson G., Johannsdottir H., Helgadottir HT., Sigurdsson A., Steinthorsdottir V., Lindblom A., Swedish Low-risk Colorectal Cancer Study Group None., Sandler RS., Keku TO., Banasik K., Jørgensen T., Witte DR., Hansen T., Pedersen O., Jinga V., Neal DE., Catalona WJ., Wrensch M., Wiencke J., Jenkins RB., Nagore E., Vogel U., Kiemeney LA., Kumar R., Mayordomo JI., Olafsson JH., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.
To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide association study of 16 million SNPs identified through whole-genome sequencing of 457 Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR) = 2.36, P = 5.2 × 10(-17)), which has a frequency of 0.0192 in the Icelandic population. We then confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P = 2.2 × 10(-20)). rs78378222 is in the 3' untranslated region of TP53 and changes the AATAAA polyadenylation signal to AATACA, resulting in impaired 3'-end processing of TP53 mRNA. Investigation of other tumor types identified associations of this SNP with prostate cancer (OR = 1.44, P = 2.4 × 10(-6)), glioma (OR = 2.35, P = 1.0 × 10(-5)) and colorectal adenoma (OR = 1.39, P = 1.6 × 10(-4)). However, we observed no effect for breast cancer, a common Li-Fraumeni syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88-1.27).